Vaccine uptake data has been examined to assess the impact of moving from a '2+1' to a '1+1' Pneumococcal Conjugate Vaccine (PCV) dose schedule on vaccine coverage and health inequalities among ...

The inequalities gap in uptake rates of pneumococcal vaccine for vulnerable groups is widening and simplifying the vaccine schedule has not reduced this, researchers from the University of Liverpool ...

Pneumococcal conjugate vaccines (PCVs) reduce disease and colonization by the serotypes they cover. As of now, the Advisory Committee on Immunization Practices (ACIP) recommends that PCV15 and PCV20 ...

After pneumococcal disease and colonization have been controlled through vaccination campaigns, a reduced pneumococcal conjugate vaccine (PCV) schedule may be sufficient to sustain that control at ...

-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability ...

1 dose ≥8wks after last PCV dose 12 No additional vaccine 6 PCV15 or PCV20 1 dose ≥8wks after last pneumococcal vaccine 8 If PCV15 used, also give PPSV23 ≥8wks after the last PCV dose if not ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...

The Centers for Disease Control and Prevention (CDC) now recommends that American adults over the age of 50 receive the pneumococcal conjugate vaccine, or PCV. The report with the updated ...

—Among adults, coverage and preventable burdens were lowest for pneumococcal conjugate vaccine (PCV) 15 and highest for PCV31, with PCV21 preventing notable burdens of both acute respiratory ...